Chronic and bedtime use of benztropine with antipsychotics: Is it necessary?

Schizophrenia Research

Volumn 153, Issue 1-3, 2014, Pages 248-249

  Wijegunaratne, Heshan ^a   Qazi, Hamid ^a   Koola, Maju Mathew ^b  

^a Xavier University School of Medicine   (Aruba)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; NEUROLEPTIC AGENT; DOPAMINE UPTAKE INHIBITOR;

BRADYKINESIA; CHOLINERGIC SYSTEM; CLINICAL TRIAL (TOPIC); COGNITION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG USE; DYSKINESIA; DYSTONIA; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETTER; MORNING DOSAGE; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM ASSESSMENT; DRUG ADMINISTRATION; MENTAL DISORDERS;

ANTIPSYCHOTIC AGENTS; BENZTROPINE; DOPAMINE UPTAKE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MENTAL DISORDERS;

EID: 84895813884     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.01.006     Document Type: Letter

References (9)

1. Baker L.A., Cheng L.Y., Amara I.B. The withdrawal of benztropine mesylate in chronic schizophrenic patients. BJP. 1983, 143:538-590.
2. Brebion G., Bressan R.A., Amador X., Malaspina D., Gorman J.M. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol. Med. 2004, 34(2):369-374.
3. Desmarais J.E., Benanclair L., Margolese H.C. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?. J. Psychopharmacol. 2012, 26(9):1167-1174.
4. Green M.F., Lee J., Ochsner K.N. Adapting social neuroscience measures for schizophrenia clinical trials, part 1: ferrying paradigms across perilous waters. Schizophr. Bull. 2013, 39(6):1192-1200.
5. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry 2001, 158(3):360-369.
6. Seeman P., Kapur S. Clozapine occupies high levels of dopamine D2 receptors. Life Sci. 1997, 60(12):PL 207-PL 216.
7. Torner C., Herrera-Estrella M., Gutierrez J.A., Aguilar-Roblero R. Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects. Int. J. Neuropsychopharmacol. 2003, 6(3):243-246.
8. Vinogradov S., Fisher M., Warm H., Holland C., Kirshner M.A., Pollock B.G. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 2009, 166(9):1055-1062.
9. Zhou X., Qi L.X., Douglas K., Palaninathan K., Constantantinidis C. Cholinergic modulation of working memory activity in primate prefrontal cortex. AJP-JN Pyshsiol. 2011, 106(5):2180-2188.